Alcidion Group

Alcidion Group Rule of 40

The Rule of 40 of Alcidion Group (ALC.AX) as of Nov 11, 2026 is 31.56 %. In the previous year, Rule of 40 was 29.20 % — a change of 8.05% (higher).

Rule of 40

31.56 %

YoY

8.05%

Last updated:

Rule of 40 of Alcidion Group is 2026 31.56 % . Rule of 40 of Alcidion Group was 2025 29.20 % . It decreases by 8.05% higher compared to the previous year.

The Alcidion Group Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
302.76 AUD
Jan 1, 2020
-2.49 AUD
Jan 1, 2021
38.84 AUD
Jan 1, 2022
21.49 AUD
Jan 1, 2023
5.90 AUD
Jan 1, 2024
-31.47 AUD
Jan 1, 2025
29.20 AUD
Jan 1, 2026
31.56 AUD
The Alcidion Group Rule of 40 history
YEARRule of 40YoY
31.56 %+8.05%
29.20 %-192.80%
-31.47 %-633.62%
5.90 %-72.56%
21.49 %-44.68%
38.84 %-1,658.65%
-2.49 %-100.82%
302.76 %-1,045.49%
-32.02 %-57.87%
-76.01 %-14.93%
-89.35 %-180.25%
111.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alcidion Group Stock analysis

What does Alcidion Group do? Alcidion Group Ltd. generates revenue through the development and licensing of its healthcare software products, including Miya Precision, Miya Observations, Flow, Task Management, and PAS, marketed under the Miya brand. The company also resells selected healthcare software from strategic partners and provides implementation, support, maintenance, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its flagship product Miya Precision, a FHIR-event platform-based solution, supports clinical and operational applications, while Smartpage offers hospital communication and task management via smartphone and web. The firm serves over 400 hospitals across its key markets. Miya Precision and its associated modules form the core of Alcidion's product portfolio, targeting hospitals seeking integrated clinical solutions. Smartpage, Patientrack, and Silverlink PCS complement these offerings, catering to diverse healthcare communication and operational needs. The company’s revenue streams are driven by direct sales of software licenses, ongoing service contracts, and partner resales, with a focus on the Australian, New Zealand, and UK healthcare sectors. Alcidion’s business model emphasizes software licensing and service delivery, with Miya Precision as the primary revenue generator. The company’s strategic partnerships enable it to resell third-party software, expanding its product range without additional development costs. Healthcare institutions in Australia, New Zealand, and the United Kingdom are the primary buyers, leveraging Alcidion’s solutions for improved clinical workflows and operational efficiency. Alcidion Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alcidion Group stock

Rule of 40 of Alcidion Group is 31.56 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 Alcidion Group since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Alcidion Group

All Key Metrics — Alcidion Group